Vincent Vultaggio - 05 Apr 2024 Form 3 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Principal Accounting Officer
Signature
/s/ Andrea Paul, attorney-in-fact for Vincent Vultaggio
Issuer symbol
ZNTL
Transactions as of
05 Apr 2024
Net transactions value
$0
Form type
3
Filing time
11 Apr 2024, 07:02:13 UTC
Next filing
04 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ZNTL Common Stock 35,458 05 Apr 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ZNTL Stock Option (Right to Buy) 05 Apr 2024 Common Stock 12,500 $18.00 Direct F1
holding ZNTL Stock Option (Right to Buy) 05 Apr 2024 Common Stock 10,000 $42.04 Direct F2
holding ZNTL Stock Option (Right to Buy) 05 Apr 2024 Common Stock 6,875 $52.61 Direct F3
holding ZNTL Stock Option (Right to Buy) 05 Apr 2024 Common Stock 2,750 $47.66 Direct F4
holding ZNTL Stock Option (Right to Buy) 05 Apr 2024 Common Stock 17,500 $23.65 Direct F5
holding ZNTL Stock Option (Right to Buy) 05 Apr 2024 Common Stock 25,000 $11.69 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were granted by the Issuer on April 2, 2020. The options vested over four years: 25% of the options vested on April 2, 2021 and the remaining 75% vested in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer.
F2 The options were granted by the Issuer on February 26, 2021. The options vest and become exercisable in 48 substantially equal monthly installments following a vesting commencement date of February 11, 2021, subject to the Reporting Person's continued service with the Issuer.
F3 The options were granted by the Issuer on February 10, 2022. The options vest and become exercisable in 48 substantially equal monthly installments following the grant date, subject to the Reporting Person's continued service with the Issuer.
F4 The options were granted by the Issuer on February 18, 2022. The options vest and become exercisable in 48 substantially equal monthly installments following a vesting commencement date of February 10, 2022, subject to the Reporting Person's continued service with the Issuer.
F5 The options were granted by the Issuer on February 1, 2023. The options vest over four years: 25% of the options vested on February 1, 2024, with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer.
F6 The options were granted by the Issuer on February 1, 2024. The options vest and become exercisable in 48 substantially equal monthly installments following the grant date, subject to the Reporting Person's continued service with the Issuer.

Remarks:

Exhibit 24 - Power of Attorney